Testing antiplatelet therapy in stroke patients with low platelet counts
Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia
This study is testing if antiplatelet medications can be safely used in stroke patients with low platelet counts to see if they help without causing too much bleeding.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou) |
| Trial ID | NCT06053021 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the safety and effectiveness of antiplatelet therapy in patients experiencing acute ischemic stroke (AIS) who also have thrombocytopenia. Participants will receive antiplatelet agents such as aspirin, clopidogrel, cilostazol, and dipyridamole, and will be monitored for a duration of three months. The study seeks to determine whether these treatments can be safely administered to this specific patient population, which is at a higher risk for bleeding complications.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have experienced an acute ischemic stroke or transient ischemic attack within the last week and have a platelet count between 30 and 100 x 10^9.
Not a fit: Patients with chronic renal dysfunction, severe hepatic injury, or those requiring anticoagulation therapy are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for AIS patients with low platelet counts, potentially improving their outcomes.
How similar studies have performed: While antiplatelet therapy is commonly used in stroke management, this specific approach in patients with thrombocytopenia is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years old * Acute ischemic stroke or transient ischemic attack with onset \< 7 days * The last blood routine test before enrollment indicates platelet count \< 100 x 10\^9 and \> 30 x 10\^9 Exclusion Criteria: * Chronic renal dysfunction (GFR \< 30ml/min) or severe hepatic injury * Indications for anticoagulation therapy, e.g. atrial fibrillation * Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past * Have or plan to receive CEA or CAS in the following 3 months * Life expectancy less than 1 year * Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding * Pregnant or lactating women * Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Where this trial is running
Hangzhou
- Second Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, China (Recruiting)
Study contacts
- Study coordinator: Min Lou, PhD
- Email: loumingxc@vip.sina.com
- Phone: +8613958007213
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.